MedTrace Logo

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

NCT05491356 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-12

No results posted yet for this study

Summary

To determine the utility of tissue plasminogen activator (tPA) in the clearance of chronic subdural hematomas (CSDH). Intra-catheter tPA will be administered during surgical procedure and allowed to break down blood clot to assist with removal/drainage during twist drill craniostomy procedure.

Conditions

  • Hematoma, Subdural
  • Fibrinolytic; Hemorrhage

Interventions

DRUG

Tissue Plasminogen Activator

Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile

DRUG

Placebo

0.9% saline solution, intra-catheter administration, sterile

Sponsors & Collaborators

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Dr. Kesava Reddy · Hamilton Health Sciences Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-11
Primary Completion
2024-03-30
Completion
2024-05-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491356 on ClinicalTrials.gov